(R)-Lisofylline is an immunomodulator and a major metabolite of Pentoxifylline and Methylxanthine. (R)-Lisofylline inhibits production of phosphatidic acid during the inflammatory response.
1.Yang Z, Chen M, Carter JD, Nunemaker CS, Garmey JC, Kimble SD, Nadler JL. (2006) Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.. Biochem Biophys Res Commun, 344 (3):(1017-22). [PMID:16643856]
2.Cui P, Macdonald TL, Chen M, Nadler JL. (2006) Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes.. Bioorg Med Chem Lett, 16 (13):(3401-5). [PMID:16650991]
3.Tersey SA, Carter JD, Rosenberg L, Taylor-Fishwick DA, Mirmira RG, Nadler JL. (2012) Amelioration of type 1 diabetes following treatment of non-obese diabetic mice with INGAP and lisofylline.. J Diabetes Mellitus, 2 (2):(251-257). [PMID:26473085]